SCHEMBL1395007

SCHEMBL1395007

Cc1nc2ccc(N3CCNC(C)(C)C3)nn2c1-c1ccnc2[nH]ccc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 5/20 0.51
ROCK2 O75116 3/20 0.38
ROCK1 Q13464 2/20 0.38
BRAF P15056 1/20 0.37
EIF2AK4 Q9P2K8 1/20 0.37
CCNK O75909 1/20 0.36
CDK12 Q9NYV4 1/20 0.36
PRKCI P41743 1/20 0.36
CDK4 P11802 1/20 0.36
JAK2 O60674 2/20 0.35
JAK1 P23458 2/20 0.35
TYK2 P29597 2/20 0.35
JAK3 P52333 1/20 0.35
ATR Q13535 4/20 0.35
AURKA O14965 1/20 0.35
AURKB Q96GD4 1/20 0.35
INCENP Q9NQS7 1/20 0.35
TPX2 Q9ULW0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1394140 0.86 CSNK1E (0.68) CSNK1EROCK2EIF2AK4
SCHEMBL1395004 0.83 CSNK1E (0.49) CSNK1EROCK2ROCK1BRAFCCNK
SCHEMBL1395006 0.83 CSNK1E (0.49) CSNK1EROCK2ROCK1BRAFCCNK
SCHEMBL1394329 0.80 CSNK1E (0.44) CSNK1EROCK2ROCK1BRAFCCNK
SCHEMBL477013 0.80 CSNK1E (0.59) CSNK1EROCK2ROCK1EIF2AK4CDK4
SCHEMBL1394527 0.79 CSNK1E (0.40) CSNK1EBRAFCCNKCDK12PRKCI
SCHEMBL1394530 0.79 CSNK1E (0.40) CSNK1EBRAFCCNKCDK12PRKCI
SCHEMBL477008 0.79 CSNK1E (0.63) CSNK1EEIF2AK4
SCHEMBL1394540 0.79 CSNK1E (0.39) CSNK1EROCK2ROCK1BRAFCCNK
SCHEMBL1394543 0.79 CSNK1E (0.39) CSNK1EROCK2ROCK1BRAFCCNK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370446-B1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-11-25 EP claimed
US-8546395-B2 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-10-01 US claimed
US-20120010208-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 US claimed
EP-2370446-B1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-11-25 EP disclosed
US-8546395-B2 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-10-01 US disclosed
US-20120010208-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010208-A1 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CBR3, CBR1, CNR1 CSNK1E 2042/4885ROCK2 925/4885ROCK1 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.